TLR3 and COVID-19: Levy and collaborators reported the safety of a single subcutaneous injection of Peg-IFN-α2a in two patients with inborn errors of the TLR-3 and IRF-7, affecting the production of type I IFNs and predisposing to severe COVID-19.